Log in

Relevant bibliographies by topics / Acamprosat

Contents

Journal articles
Dissertations / Theses
Books
Book chapters
Conference papers
Reports

Academic literature on the topic 'Acamprosat'

Author: Grafiati

Published: 4 June 2021

Last updated: 27 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Acamprosat.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Acamprosat"

1

Kiefer, Falk, Holger Jahn, Rüdiger Holzbach, Peer Briken, Robert Stracke, and Klaus Wiedemann. "Die NALCAM-Studie: Wirksamkeit, Verträglichkeit, Outcome." SUCHT 49, no. 6 (2003): 342–51. http://dx.doi.org/10.1024/suc.2003.49.6.342.

Full text

Abstract:

Ziel: Vergleich der Effektivität und Verträglichkeit von Naltrexon und Acamprosat in der Rückfallprophylaxe bei Alkoholabhängigkeit. </P><P>Methodik: Doppelblinde, placebo-kontrollierte Studie. Einschluss von 160 Patienten nach stationärem Alkoholentzug. Behandlung mit Naltrexon, Acamprosat, Naltrexon plus Acamprosat vs. Placebo im Rahmen eines ambulanten Therapieprogramms. Analyse der Behandlungseffekte nach 12 Wochen und im Follow-up. </P><P>Ergebnisse: Naltrexon, Acamprosat und Kombinations

APA, Harvard, Vancouver, ISO, and other styles

2

Fuchs and Riebenfeld. "Acamprosat und psychosoziale Intervention." Praxis 91, no. 17 (2002): 735–42. http://dx.doi.org/10.1024/0369-8394.91.17.735.

Full text

Abstract:

105 patients présentant une forte dépendance à l'alcool et traités dans 13 centres de Suisse ont pris part à cette étude ouverte. Pendant une période de 24 semaines, le taux d'abstinence a été déterminé sous acamprosate utilisé dans le cadre de programmes psychothérapeutiques d'intervention établis, les médecins ayant le choix entre cinq procédés différents. En outre, un profil socio-démographique a été établi. Il a été procédé à un examen physique et des données touchant à la tolérance de l'acamprosate ont été récoltées. Il était de plus intéressant de vérifier si la qualité de vie se modifia

APA, Harvard, Vancouver, ISO, and other styles

3

Soyka, Michael. "Pharmakologische Rückfallprophylaxe der Alkoholabhängigkeit." Nervenheilkunde 40, no. 08 (2021): 628–35. http://dx.doi.org/10.1055/a-1513-9420.

Full text

Abstract:

ZUSAMMENFASSUNGNur wenige Substanzen sind als sogenannte Anti-Craving-Me-dikamente zur pharmakogestützten Rückfallprophylaxe der Alkoholabhängigkeit zugelassen. Dazu gehören das in Deutschland nicht mehr vertriebene Disulfiram, die Opioidantagonisten Naltrexon und Nalmefen sowie Acamprosat. Gerade für Acamprosat und Naltrexon ist die Evidenzbasierung recht gut, bei mäßiger, aber klinisch signifikanter Effizienz. Sie werden trotzdem selten eingesetzt. Interessante Substanzen mit klinischer Perspektive sind am ehesten Baclofen, Vareniclin und Gabapentin. Die klinischen Befunde und Perspektiven d

APA, Harvard, Vancouver, ISO, and other styles

4

Soyka, M., and W. Zieglgänsberger. "Rückfallprophylaxe der Alkoholabhängigkeit mit Acamprosat." Der Internist 40, no. 3 (1999): 330–36. http://dx.doi.org/10.1007/s001080050341.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Wiedemann, K., and F. Kiefer. "Zur differenziellen Indikationsstellung von Anti-Craving-Substanzen bei Alkoholabhängigkeit." Nervenheilkunde 23, no. 09 (2004): 521–26. http://dx.doi.org/10.1055/s-0038-1626417.

Full text

Abstract:

ZusammenfassungDie Wirksamkeit der medikamentösen Rückfallprophylaxe in der Behandlung der Alkoholabhängigkeit wurde insbesondere für Acamprosat und Naltrexon nachgewiesen. Dennoch ist unklar, inwieweit eine pharmakologische Behandlung unabhängig von der individuellen Charakteristik des behandelnden Patienten wirksam ist. So stellt sich die Frage nach differenzierten Indikationskriterien. Aktuelle Studienergebnisse geben Hinweise darauf, dass Symptome wie Angst, Depression, somatische Störungen und Suchtdruck, aber auch typologische Differenzierungen hilfreich sein können, die Wirksamkeit der

APA, Harvard, Vancouver, ISO, and other styles

6

Rychlik, R., B. Paschen, D. Kirchhoff, D. Daniel, T. Pfeil, and A. Kilburg. "Die adjuvante Arzneimitteltherapie der Alkoholkrankheit mit Acamprosat." DMW - Deutsche Medizinische Wochenschrift 126, no. 33 (2001): 899–904. http://dx.doi.org/10.1055/s-2001-16502.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Schönfeldt-Lecuona, C., and M. Gahr. "Acamprosat und Naltrexon als Kombinationstherapie bei Alkoholund Benzodiazepinabhängigkeit." Nervenheilkunde 32, no. 01/02 (2013): 54–57. http://dx.doi.org/10.1055/s-0038-1628472.

Full text

Abstract:

ZusammenfassungAcamprosat und Naltrexon sind etablierte Strategien zur pharmakologischen Rückfallprophylaxe bei Patienten mit Alkoholabhängigkeit. Obwohl die Kombination beider Substanzen bei dieser Indikation aufgrund pharmakodynamischer und -kinetischer Überlegungen eine sinnvolle Therapieoption darstellt, welche in klinischen Studien als effektiv und sicher beschrieben wurde, wird sie im klinischen Alltag selten eingesetzt. Wir berichten über eine erfolgreiche Behandlung von Acamprosat und Naltrexon bei einer Patientin mit einer schweren Alkohol-und Benzodiazepinabhängigkeit, welche unter d

APA, Harvard, Vancouver, ISO, and other styles

8

Gahr, M., M. A. Kölle, and C. Schönfeldt-Lecuona. "Rückfallprävention bei Alkoholabhängigkeit: Acamprosat und Naltrexon als kombinierte pharmakologische Strategie." Der Nervenarzt 84, no. 5 (2012): 584–89. http://dx.doi.org/10.1007/s00115-012-3633-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Engelhard, K., C. Werner, H. Lu, O. Möllenberg, W. Zieglgänsberger, and E. Kochs. "Der neuroprotektive Einfluss des Glutamat-Antagonisten Acamprosat nach experimenteller zerebraler Ischämie." Der Anaesthesist 49, no. 9 (2000): 816–21. http://dx.doi.org/10.1007/s001010070054.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Gallinat, J., M. Soyka, S. Ufer, et al. "EEG and event related potentials as indicators of central neurophysiological effects of acamprosat." Biological Psychiatry 42, no. 1 (1997): 215S. http://dx.doi.org/10.1016/s0006-3223(97)87799-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

More sources

Dissertations / Theses on the topic "Acamprosat"

1

Rösner, Susanne. "Meta-Analyse zur Wirksamkeit von Acamprosat und Naltrexon in der Entwöhnungsbehandlung alkoholabhängiger Patienten." Diss., lmu, 2006. http://nbn-resolving.de/urn:nbn:de:bvb:19-61877.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Lange, Inga Eva Stik. "Estudo dos efeitos dos psicofármacos acamprosato e levomepromazina sobre as formas epimastigotas e tripomastigotas do Trypanosoma cruzi in vitro." Universidade de São Paulo, 2012. http://www.teses.usp.br/teses/disponiveis/42/42135/tde-21092012-083842/.

Full text

Abstract:

Nosso laboratório vem trabalhando no metabolismo de GABA, projeto derivado de estudos da via prolinaglutamato em T. cruzi. Os efeitos dos psicofarmacos, acamprosato e levomepromazina, em diferentes aspectos da biologia do T. cruzi apontam estes como compostos líderes para o desenho de novas drogas com capacidade terapêutica otimizada contra o T. cruzi.<br>Our laboratory has been working on the metabolism of the GABA in T. cruzi, a project derived from studies on the prolineglutamate pathway in this organism. The effects of two psycodrugs, acamprosate and levomepromazine, showed that both could

APA, Harvard, Vancouver, ISO, and other styles

3

Baltieri, Danilo Antonio. ""Utilização do acamprosato no tratamento de dependentes de álcool"." Universidade de São Paulo, 2002. http://www.teses.usp.br/teses/disponiveis/5/5142/tde-05092006-232745/.

Full text

Abstract:

A eficácia e a segurança do acamprosato foram avaliadas no tratamento ambulatorial de setenta e cinco pacientes do sexo masculino, com idade entre 18 e 59 anos, com diagnóstico de dependência de álcool pelo CID-10. O estudo foi controlado duplo-cego, com duração de 24 semanas. Transtornos clínicos e/ou psiquiátricos que necessitassem de internação, uso de medicação psiquiátrica, quadros psicóticos prévios independentes do consumo de álcool e hipersensibilidade ao acamprosato foram critérios de exclusão. Após um período de desintoxicação de uma semana, os pacientes foram divididos aleatoriament

APA, Harvard, Vancouver, ISO, and other styles

4

Zornoza, Sabina Teodoro. "Estudios farmacocinéticos y biofarmacéuticos del acamprosato en la rata." Doctoral thesis, Universitat de València, 2003. http://hdl.handle.net/10803/9756.

Full text

Abstract:

El acamprosato o bis-acetilhomoaurinato cálcico es un fármaco que se emplea en la terapia de mantenimiento de la abstinencia en pacientes dependientes del alcohol. Sin embargo, uno de los problemas más importantes en su manejo clínico deriva de su reducida biodisponibilidad oral en magnitud (BD), que se sitúa en torno a un 11% en humanos. Por ello, mediante el empleo de diversos y sencillos diseños experimentales se ha abordado el estudio de dos de los procesos menos conocidos de su farmacocinética, la absorción y la eliminación. El estudio de la linealidad farmacocinética del acamprosato se h

APA, Harvard, Vancouver, ISO, and other styles

5

JOUVENTIN, PATRICK. "Le sevrage alcoolique en hopital general : role de l'acamprosate." Aix-Marseille 2, 1994. http://www.theses.fr/1994AIX20169.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Capbert, Nathalie. "Espéral (R), Aotal (R) : traitement de l'alcoolisme." Bordeaux 2, 1996. http://www.theses.fr/1996BOR2P037.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

LEICHTNAM, ALAIN. "Effet de l'alcoolisme sur la transmission gabaergique : utilisation de l'aotal r." Strasbourg 1, 1994. http://www.theses.fr/1994STR15043.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Mas, Serrano Patricio. "Estudio del mecanismo de absorci¨®n intestinal del acamprosato en la rata." Doctoral thesis, Universitat de València, 2005. http://hdl.handle.net/10803/9759.

Full text

Abstract:

El acamprosato, comercializado en varios pa¨ªses de la Uni¨®n Europea yautorizado recientemente en EE.UU., est¨¢ indicado en la terapia de mantenimiento dela abstinencia en pacientes dependientes al alcohol sometidos a tratamientodeshabituador. Este f¨¢rmaco presenta como principal problema su bajabiodisponibilidad oral en humanos (aproximadamente un 10%) cuando se administraen forma de comprimidos con recubrimiento gastrorresistente. A pesar de losnumerosos estudios realizados, en el momento de la realizaci¨®n de la presentememoria se desconoc¨ªan aspectos relevantes de su farmacocin¨¦tica, c

APA, Harvard, Vancouver, ISO, and other styles

9

DEL, BIANCO MANUELA. "Le sevrage de l'alcoolique et son maintien : role du medicament." Strasbourg 1, 1994. http://www.theses.fr/1994STR15022.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Brager, Allison Joy. "Roles of the circadian and reward systems in alcoholism." Kent State University / OhioLINK, 2011. http://rave.ohiolink.edu/etdc/view?acc_num=kent1306869438.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "Acamprosat"

1

Soyka, Michael, ed. Acamprosate in Relapse Prevention of Alcoholism. Springer Berlin Heidelberg, 1996. http://dx.doi.org/10.1007/978-3-642-80193-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Acamprosate in relapse prevention of alcoholism. Springer, 1996.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

3

Blokdijk, G. J. Acamprosate Calcium; Third Edition. CreateSpace Independent Publishing Platform, 2018.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

4

Soyka, Michael. Acamprosate in Relapse Prevention of Alcoholism. Springer London, Limited, 2012.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

5

Soyka, Michael. Acamprosate in Relapse Prevention of Alcoholism. Springer, 2011.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

6

Acamprosate in Relapse Prevention of Alcoholism. Island Press, 1996.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

7

Evaluación de algunas estrategias en el tratamiento de la dependencia alcohólica (influencia de antagonistas opiáceos y acamprosato). Instituto de Salud Carlos III, 2002. http://dx.doi.org/10.4321/repisalud.4981.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Bryan, Benjamin R., and Frances R. Levin. Substance-Related and Addictive Disorders. Oxford University Press, 2014. http://dx.doi.org/10.1093/med/9780199326075.003.0007.

Full text

Abstract:

Alcohol use disorder tends to have a progressive course with varying outcomes. The rate of onset of a drug’s effects and the rate at which the effects diminish or are lost affect the evolution of a drug use pattern into a substance use disorder. Depression, psychosis, anxiety, and delirium are all common symptoms associated with drug use. Many patients underestimate the amount of alcohol or drugs they use when asked by a physician. Patients with addictive behaviors demonstrate varying degrees of denial. Evidence-based psychotherapeutic interventions for the treatment of substance use disorders

APA, Harvard, Vancouver, ISO, and other styles

9

McKay, James R., Henry R. Kranzler, Kyle M. Kampman, Rebecca L. Ashare, and Robert A. Schnoll. Psychopharmacological Treatments for Substance Use Disorders. Oxford University Press, 2015. http://dx.doi.org/10.1093/med:psych/9780199342211.003.0024.

Full text

Abstract:

The treatment of substance use disorders with medications is well established, although most experts agree that pharmacological interventions must be combined with psychosocial therapies. Many type 1 and type 2 controlled trials have shown that the use of nicotine replacement therapy significantly increases abstinence rates. Non-nicotine treatments, such as bupropion and varenicline, have been found in controlled trials to significantly increase abstinence rates. The treatment of alcohol use disorder can be enhanced by three approved medications with different mechanisms of action: disulfiram,

APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Acamprosat"

1

Benkert, Otto, Ion Anghelescu, Christoph Fehr, et al. "Acamprosat." In Pocket Guide Psychopharmaka von A bis Z. Springer Berlin Heidelberg, 2010. http://dx.doi.org/10.1007/978-3-642-01910-4_1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Peter, Helga, and Thomas Penzel. "Acamprosat." In Springer Reference Medizin. Springer Berlin Heidelberg, 2020. http://dx.doi.org/10.1007/978-3-642-54672-3_289-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Peter, Helga, and Thomas Penzel. "Acamprosat." In Springer Reference Medizin. Springer Berlin Heidelberg, 2025. https://doi.org/10.1007/978-3-662-65186-5_289.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Trenckmann, U., and B. Bandelow. "Acamprosat (Campral®)." In Psychiatrie und Psychotherapie. Steinkopff, 1999. http://dx.doi.org/10.1007/978-3-642-58700-9_22.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Mason, Barbara J. "Acamprosate." In Recent Developments in Alcoholism. Springer US, 2002. http://dx.doi.org/10.1007/0-306-47939-7_16.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Mason, Barbara J., and Charles J. Heyser. "Acamprosate." In Encyclopedia of Psychopharmacology. Springer Berlin Heidelberg, 2015. http://dx.doi.org/10.1007/978-3-642-36172-2_163.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Scherrmann, Jean-Michel, Kim Wolff, Christine A. Franco, et al. "Acamprosate." In Encyclopedia of Psychopharmacology. Springer Berlin Heidelberg, 2010. http://dx.doi.org/10.1007/978-3-540-68706-1_163.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Mason, Barbara J., and Charles J. Heyser. "Acamprosate." In Encyclopedia of Psychopharmacology. Springer Berlin Heidelberg, 2014. http://dx.doi.org/10.1007/978-3-642-27772-6_163-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

De Witte, Philippe, Daniel Bachteler, and Rainer Spanagel. "Acamprosate: preclinical data." In Drugs for Relapse Prevention of Alcoholism. Birkhäuser Basel, 2005. http://dx.doi.org/10.1007/3-7643-7305-9_7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Lovinger, D. M. "Ethanol and the NMDA Receptor: Implications for Intoxication, Tolerance, Dependence, and Alcoholic Brain Damage." In Acamprosate in Relapse Prevention of Alcoholism. Springer Berlin Heidelberg, 1996. http://dx.doi.org/10.1007/978-3-642-80193-8_1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Acamprosat"

1

"ACAMPROSATE INDUCED PARKINSONISM: EXTREMELY RARE ADVERSE EFFECT." In 8th World Congress of the World Association of Dual Disorders (WADD) and the 26th Congress of the Spanish Society of Dual Disorders SEPD. SEPD/WADD, 2024. http://dx.doi.org/10.17579/abstractbookdualdisorders-p-140.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Tybel, Mariana Jordem Filgueiras, Mirele Morais Mayrink, Melina Salarini Mendonça, et al. "CONTROLE MOTOR E NEUROCOGNIÇÃO EM CRIANÇAS AUTISTAS: UMA REVISÃO INTEGRATIVA SOBRE O EFEITO DA TAURINA." In V Seven International Congress of Health. Seven Congress, 2025. https://doi.org/10.56238/sevenvhealth2025-010.

Full text

Abstract:

A taurina é um dos aminoácidos não-essenciais mais abundantes no nosso organismo, tendo importante função no desenvolvimento cognitivo. Variações em sua concentração estão relacionadas à distúrbios do neurodesenvolvimento, exemplificados por movimentos repetitivos, hiperatividade e déficit interativo em crianças autistas. Estudos demonstram que a suplementação do acamprosato, fármaco derivado da taurina, apresenta um potencial mecanismo farmacodinâmico na melhora dos sintomas cognitivos e motores. Sob essa ótica, o trabalho tem como objetivo analisar os dados relativos à influência da suplemen

APA, Harvard, Vancouver, ISO, and other styles

3

Gómez-Carreño, Carlos Rodríguez, Antonio Ramírez García, Luis Beato Fernández, Irene Díaz Quero, and Estefanía Segura Escobar. "Craving and Priming of alcohol in depressive disorders. Bibliographic review and new therapies." In 22° Congreso de la Sociedad Española de Patología Dual (SEPD) 2020. SEPD, 2020. http://dx.doi.org/10.17579/sepd2020p140.

Full text

Abstract:

Acute alcohol consumption produces positive reinforcement effects, through activation of brain reward circuit, includes limbic system structures (accumbens system and hippocampus). The comorbidity of depressive episode and alcohol abuse makes it necessary to propose new strategies for the treatment of this frequent clinical situation. We conducted a literature review of the combined treatments for major depressive disorder (MDD) with alcohol abuse. We review current literature on the use of new treatments in alcohol consumption with pattern of abuse (binge drinking). Recent studies support the

APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Acamprosat"

1

McPheeters, Melissa, Elizabeth A. O'Connor, Sean Riley, et al. Pharmacotherapy for Adults With Alcohol Use Disorder in Outpatient Settings: Systematic Review. Agency for Healthcare Research and Quality (AHRQ), 2023. http://dx.doi.org/10.23970/ahrqepccer262.

Full text

Abstract:

Background. Unhealthy alcohol use is the third leading preventable cause of death in the United States, accounting for more than 140,000 deaths annually. Only 0.9 percent of Americans who reported having alcohol use disorder (AUD) in the past year indicated they received medication-assisted AUD treatment. Methods. We updated a 2014 Agency for Healthcare Research and Quality (AHRQ) report on pharmacotherapy for AUD treatment, following AHRQ Evidence-based Practice Center Guidance. We assessed efficacy and comparative effectiveness of specific medications for improving consumption outcomes (Key

APA, Harvard, Vancouver, ISO, and other styles

2

Kennedy, Sara M., and Rania Ali. Baclofen for Alcohol Use Disorder: A Cochrane Review Summary With Commentary. RTI Press, 2025. https://doi.org/10.3768/rtipress.2025.rb.0040.2502.

Full text

Abstract:

This brief summarizes the Cochrane Review, “Baclofen for Alcohol Use Disorder,” by R. Agabio, R. Saulle, S. Rösner, and S. Minozzi (https://doi.org/10.1002/14651858.CD012557.pub3). The Cochrane Review examines evidence for benefits and harms of baclofen on achieving and maintaining abstinence or reducing alcohol consumption in people with alcohol use disorder (AUD) compared to placebo, no treatment, or any other pharmacological relapse prevention treatment. Review authors conclude that baclofen likely reduces the risk of relapse to any drinking and increases the percentage of abstinent days, m

APA, Harvard, Vancouver, ISO, and other styles

3

Alcohol dependence: telephone support plus financial incentives helped people take acamprosate. National Institute for Health Research, 2024. http://dx.doi.org/10.3310/nihrevidence_62108.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!